A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Hematologic Malignancies (HM) Program Bookmark and Share

Hematologic Malignancies (HM) Program

Stephen J. Forman, M.D., Co-leader
Wing-Chung (John) Chan, M.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.

The long-term goal of the Hematologic Malignancies (HM) Program is to improve outcomes for patients with leukemia, lymphoma, Hodgkin's disease and multiple myeloma. HM integrates basic, translational and clinical research related to the pathogenesis and treatment of hematologic malignancies through close collaborations between basic and clinical researchers. The major areas of focus are to (a) expand opportunities and optimize outcomes for potentially curative treatment with autologous and allogeneic transplantation, (b) increase understanding of malignant stem cells in hematologic malignancies to improve cures and c) develop new, nontransplant experimental therapies for hematologic malignancies.

Recently, HM has expanded research in nontransplant therapeutics and leukemia biology. The success of monoclonal antibodies such as Rituxan (rituximab) and Campath (alemtuzumab) in the treatment of chronic lymphocytic leukemia and novel small molecules such as Gleevec (imatinib) in chronic myelogenous leukemia has made this area fertile ground for study.

Clinical and research programs have been established for specific disease entities, including acute and chronic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma.  With clinical and basic scientists working together, this creates an expanded repertoire of studies focused on individual diseases, which complements our transplant modality-driven investigations. The HM Program then shares results of these studies with researchers and clinicians in other Cancer Center Programs.

Program Goals

  •  Develop novel autologous and allogeneic transplant regimens to improve safety and efficacy of treatment, and expand their use to underserved populations including patients with HIV and older people with hematologic malignancy.
  • Study mechanisms regulating  normal and malignant hematopoietic stem cells (HSCs), and develop therapies based on manipulating normal HSCs and interventions targeting malignant stem cells.
  • Develop novel non-transplant therapeutic studies of epigenetic mechanisms, molecular targets of gene expression, RNAi and immune-based treatments.

HM Members' Research
Members of the HM Program design and lead phase I/II clinical trials using novel therapies for hematologic malignancies. The expertise represented by this group includes cytogenetics and molecular diagnostics, pathology, hematopoietic cell transplantation and graft-versus-host disease, gene- and cell-based therapies, stem cell research and biostatistics. Members of this program collaborate closely with other research programs, including Developmental Cancer Therapeutics and Cancer Immunotherapeutics, for development of small molecule- and immunological-based cancer therapeutics.
 

Hematologic Malignancies (HM) Program

Hematologic Malignancies (HM) Program

Stephen J. Forman, M.D., Co-leader
Wing-Chung (John) Chan, M.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.

The long-term goal of the Hematologic Malignancies (HM) Program is to improve outcomes for patients with leukemia, lymphoma, Hodgkin's disease and multiple myeloma. HM integrates basic, translational and clinical research related to the pathogenesis and treatment of hematologic malignancies through close collaborations between basic and clinical researchers. The major areas of focus are to (a) expand opportunities and optimize outcomes for potentially curative treatment with autologous and allogeneic transplantation, (b) increase understanding of malignant stem cells in hematologic malignancies to improve cures and c) develop new, nontransplant experimental therapies for hematologic malignancies.

Recently, HM has expanded research in nontransplant therapeutics and leukemia biology. The success of monoclonal antibodies such as Rituxan (rituximab) and Campath (alemtuzumab) in the treatment of chronic lymphocytic leukemia and novel small molecules such as Gleevec (imatinib) in chronic myelogenous leukemia has made this area fertile ground for study.

Clinical and research programs have been established for specific disease entities, including acute and chronic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma.  With clinical and basic scientists working together, this creates an expanded repertoire of studies focused on individual diseases, which complements our transplant modality-driven investigations. The HM Program then shares results of these studies with researchers and clinicians in other Cancer Center Programs.

Program Goals

  •  Develop novel autologous and allogeneic transplant regimens to improve safety and efficacy of treatment, and expand their use to underserved populations including patients with HIV and older people with hematologic malignancy.
  • Study mechanisms regulating  normal and malignant hematopoietic stem cells (HSCs), and develop therapies based on manipulating normal HSCs and interventions targeting malignant stem cells.
  • Develop novel non-transplant therapeutic studies of epigenetic mechanisms, molecular targets of gene expression, RNAi and immune-based treatments.

HM Members' Research
Members of the HM Program design and lead phase I/II clinical trials using novel therapies for hematologic malignancies. The expertise represented by this group includes cytogenetics and molecular diagnostics, pathology, hematopoietic cell transplantation and graft-versus-host disease, gene- and cell-based therapies, stem cell research and biostatistics. Members of this program collaborate closely with other research programs, including Developmental Cancer Therapeutics and Cancer Immunotherapeutics, for development of small molecule- and immunological-based cancer therapeutics.
 
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Clinical Trials
Our aggressive pursuit to discover better ways to help patients now – not years from now – places us among the leaders worldwide in the administration of clinical trials.
 
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Discover the wide range of progressive cancer treatment options at City of Hope designed to meet the individual needs of each patient. Here, medical research and clinical care are integrated, speeding the application of scientific discoveries toward better, more effective patient cancer treatments.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 
When you support City of Hope, you help us shorten the time it takes to get from bold, innovative ideas to powerful new medical treatments. Make a gift online now.


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...